Brivaracetam (BRV) was approved in 2016 as a new antiepileptic drug (AED) for the adjunctive pharmacological treatment of focal-onset seizures with or without secondary generalization. Meanwhile BRV was also approved as monotherapy. BRV is a derivative of levetiracetam (LEV) with a 15- to 30-fold higher affinity to ubiquitous synaptic vesicle glycoprotein 2A [1].

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...